ADC Drug Map
CLICK ON THE HUMAN TO SEE WHICH ADCs ARE BEING DEVELOPED FOR THAT SPECIFIC ORGAN
Filter by Cancer
- Bladder cancer
- Myeloma
- Leukemia
- Breast cancer
- Colon cancer
- Esophageal cancer
- Kidney cancer
- Colorectal cancer
- Liver cancer
- Lung cancer
- Hodgkin's disease
- Lymphoma
- Mesenteric Lymphadenitis
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Rectal cancer
- Skin cancer
- Small Intestine cancer
- Spleen cancer
- Stomach cancer
- Uterine cancer
- White blood cells
ADC
- AB-3A4 ADCAlethia Biotherapeutics
- ABBV-176 (ABV176)Abbvie
- AbGn-107 (Ab1-18Hr1)AbGenomics BV | Taiwan Branch
- AbGn-108AbGenomics International
- AbGn-110AbGenomics International
- ADCT-502ADC Terapeutics
- ADCT-601ADC Therapeutics
- ADCT-602 (hLL2-cys-PBD)ADC Therapeutics
- ADCT-701ADC Therapeutics
- AGS-16C3F (AGS 16C3F / AGS-16M8F)Agensys/Astellas
- AGS-16M8F (AGS 16C3F / AGS-16C3F)Agensys/Astellas
- AGS-22M6EAstellas Pharma Inc/Agensys, Inc. Seattle Genetics, Inc.
- AGS62P1Agensys/Astellas
- ALT-P73SBIO | Alteogen
- AMG 224Amgen
- AMG-595Amgen
- AMG172Amgen, Inc
- Anetumab Ravtansine (BAY 94-9343)Bayer HealthCare Pharmaceuticals in association with ImmunoGen Inc.
- Anti-ADAM9 ADC (Anti-ADAM9-sulfoSPDB-DM4)Macrogenics and ImmunoGen
- Anti-ADAM9 ADC (Anti-ADAM9(C442)-DGN549)Macrogenics and ImmunoGen
- Anti-CD19 ATAC (anti-CD19 ADC)Heidelberg Pharma/Wilex
- Anti-CD22-NMS249Genentech and Nerviano Medical Sciences
- Anti-CD70-ADC (CD70-ADC)Ambrx
- Anti-cMET ADC (CBT-161)Sorrento Therapeutics
- Anti-endosialin-MC-VC-PABC-MMAEGenzyme
- Anti-ETBR (RG-7636)Genentech/Roche
- anti-HER-3 ADCMediaPharma
- anti-TEM-1 Antibody-Drug Conjugate (TEM-1-ADC).MediaPharma S.r.l.
- Anti-TM4SF1 ADCThe Center for Vascular Biology Research and the Departments of Angiex; Pfizer; Pathology, Beth Israel Deaconess Medical Center (BIDMC); Harvard Medical School, Boston, Massachusetts
- Aprutumab ixadotin (BAY 1187982)Bayer HealthCare Pharmaceuticals
- AR-001 | YBL-001Y-Biologics
- ARX517-PSMA-ADCAmbrx
- ARX788 HER2 ADCZhejiang Medicine Co. | Ambrx
- ASG-22CEAstellas Pharma Inc/Agensys, Inc. Seattle Genetics, Inc.
- ASG-5MEAgensys/Astellas
- ASN-004 (ASN 004)Asana Biosciences
- AVID100Formation Biologics
- AVID300 | AVID 300Formation Biologics
- Azintuxizumab vedotin (ABBV-838)AbbVie
- Azonafide-ADCOncolinx
- BA3011 | CAB-Axl-ADC (CAB-anti-Axl-ADC)BioAtla
- BA3021 | Anti-ROR2 ADC | CAB-ROR2-ADCBioAtla
- BAY79-4620Bayer HealthCare
- Belantamab mafodotin
- BIIB-015 | BIIB015Biogen
- Bivatuzumab mertansine | Anti-CD44v6-DM1 | BIWI-1Boehringer Ingelheim | ImmunoGen
- Brentuximab vedotin (SGN35 / Adcetris®)Seattle genetics, Inc. (Bothell WA USA) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan)
- Bstrongximab-ADCCureMeta
- BT1718 (BT 1718)Bicycle Therapeutics
- c-MET ADCConcortis Biotherapeutics
- Camidanlumab tesirine (ADCT-301 | HuMax-TAC-ADC)Genmab | ADC Therapeutics
- Cantuzumab mertansine | huC242-DM1 | SB-408075GlaxoSmithKline (GSK) / ImmunoGen
- Cantuzumab Ravtansine (IMGN-242)ImmunoGen
- CD184-Dasatinib (CD184-Dasatinib-ADC)Ambrx
- CD184-FK506Ambrx
- CD22-4APCatalent Pharma Solutions and Triphase Accelerator Corporation
- CD70-glucocorticoid ADCMerck & Co and Ambrx
- CDX-014Celldex Therapeutics
- Cirmtuzumab Vedotin | UC-961ADC3Thomas Kipps, University of California, San Diego
- Clivatuzumab TetraxetanImmunmedics
- CMB-401 | hCTMO1-calicheamicin | CDP-671Pfizer (Wyeth Pharmaceuticals); Celltech
- Cofetuzumab pelidotin (PF-06647020)Pfizer / Stemcentrx (AbbVie)
- Coltuximab Ravtansine (SAR 3419)ImmunoGen (previously also Sanofi)
- CX-2009Cytomx
- Cymac-001 (anti-CD163-dexamethasone ADC)Affinicon
- D3-GPC2-PBD (anti-GPC2 ADC)Children's Hospital of Philadelphia (CHOP
- DEDN6526A (RG-7636 / RG7636)Genentech/Roche
- Denintuzumab mafodotin (SGN-CD19A / SGN-19A)Seattle Genetics
- Depatuxizumab Mafodotin | ABT-414AbbVie (prior sponsor, Abbott)
- DMOT4039A (DMOT-4039A / RG7600 / RG 7600)Genentech Inc. (South San Francisco, CA, USA) / Roche, F. Hoffmann-La Roche Ltd. (Basel, Switzerland)
- DS-1062 (TROP2 ADC)Daiichi Sankyo
- DS-7300 (B7-H3 ADC)Daiichi Sankyo Company
- DSTA4637S (Anti-S. aureus TAC; RG7861)Genentech
- EC1169Endocyte
- EC2629Endocyte
- EDC1 (DYS-ADC)Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)
- EDC9 (EDC-CD20)Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)
- EDO-772P/B776Mundipharma EDO GmbH
- EDO-B278Mundipharma EDO GmbH
- Enapotamab vedotin | HuMax-AXL-ADC | AXL-107-MMAEGenmab
- Enfortumab Vedotin (ASG-22ME / ASG-22MSE)Agensys (Santa Monica CA USA) / Seattle Genetics (Bothell WA USA) and Astellas Pharma (Tokyo, Japan).
- EP-400Esperance Pharmaceuticals
- Epratuzumab–SN-38Immunomedics
- EV20/MMAFMediapharma
- Gemtuzumab ozogamicin (Mylotarg®)Pfizer (Wyeth)
- Glembatumumab vedotin (CDX-011)Celldex Therapeutics, Inc.
- GM103GamaMabs
- GSK2857916 (J6M0-mcMMAF)GSK
- HDP-101 (Anti-CD269-ADC; Anti-CD269-amanitin-ADC)Heidelberg Pharma
- Hertuzumab VedotinRongchang Pharmaceuticals / MabPlex (Yantai, China).
- HKT288 (CDH6-ADC)Novartis and ImmunoGen
- HTI-1511Halozyme
- HuMAB-5B1-ATACWilex/Heidelberg Pharma in collaboration with MabVax
- IGN523Igenica Biotherapeutics
- IGN786Igenica Biotherapeutics
- Iladatuzumab vedotin (DCDS0780A; RO7032005)F. Hoffmann-La Roche
- IMAB027-vcMMAEGanymed Pharmaceuticals | Astellas
- IMAB362-vcMMAEAstellas (Ganymed Pharmaceuticals)
- IMB-201ImmunoBiochem
- IMB-202ImmunoBiochem
- IMGN 289ImmungoGen
- IMGN 779 | IMGN779ImmunoGen, Inc.
- IMGN-242ImmunoGen
- IMGN-388ImmunoGen
- IMGN-633 (AVE9633)ImmunoGen
- IMGN632 | IMGN 632ImmunoGen
- IMMU-140 (anti-HLA-DR-SN-38 ADC)Immunomedics
- Indatuximab Ravtansine | BT-062ImmunoGen | BioTest
- Industuzumab Vedotin (MLN-0264 | TAK-264)Takeda / Millennium Pharmaceuticals
- Inotuzumab ozogamicin (CMC-544) | BESPONSA®Pfizer (Wyeth Pharmaceuticals)
- KTN0125Kolltan Pharmaceuticals
- KTN0182AKolltan Pharmaceuticals
- Labetuzumab govitecan (IMMU-130)Immunomedics
- Ladiratuzumab vedotin (SGN-LIV1A; Anti-LIV-1 ADC)Seattle Genetics
- Laprituximab emtansine (IMGN-289, IMGN289)ImmunoGen
- LCB14-0110 (Herceptin-LC-LBG-MMAF)Legochem Biosciences and Fosun Pharma
- LCB14-15nmLegoChem Biosciences and Takeda
- LCB14-15xxLegoChem Biosciences and Y-Biologics
- LCB14-15xx (NNV019)LegoChem Biosciences and Nordic Nanovector
- LCB14-17nnLegoChem Biosciences and Gree Cross
- LCB14-19nmLegoChem Biosiences and Samsung Medical Center
- LCB14-2nmLegoChem Biosciences and Seasun Biomaterials
- Lifastuzumab Vedotin (RG-7599 / DNIB0600A)Roche, F. Hoffmann-La Roche / Genentech
- Loncastuximab tesirine (ADCT-402)ADC Therapeutics SARL
- LOP628 (LOP-628)Novartis Pharmaceuticals
- Lorvotuzumab mertansine (IMGN-901)ImmunoGen
- Losatuxizumab vedotin (ABBV-221)AbbVie
- Lupartumab amadotin (BAY 1129980)Bayer
- LY3076226Eli Lilly and Company
- MDX-060 / iratumumabMedarex/Bristol-Myers Squibb
- MDX-1203 | BMS936561Medarex | Bristol-Myers Squibb
- MEDI-547MedImmune
- MEDI3726 | ADCT-401ADC Therapeutics in collaboration with MedImmune/AstraZeneca
- MEDI4276 (MEDI 4276)Medimmune / AstraZeneca
- MEN1309 | OBT076Co-developed by Menarini Ricerche and Oxford BioTherapeutics
- MGC018; Anti-B7-H3 ADCMacroGenics
- MI130004PharmaMar
- Milatuzumab doxorubicin (hLL1-DOX | IMMU-110)Immunomedics
- Mirvetuximab Soravtansine (IMGN-853)ImmunoGen (Cambridge MA USA)
- MLN-2704 | MLN2704Millennium/ Takeda
- MM-302Merrimack Pharmaceuticals, Inc.
- MORAb-202Morphotek®, a subsidiary of Eisai
- Naratuximab emtansine (IMGN529 | K7153A) | Debio 1562 )ImmunoGen | Debiopharm Internaltional
- NBE-002NBE Therapeutics GmbH
- NC-6201 (ADCM-E7974)NanoCarrier Co.,Ltd (Japan) and Eisai
- NV101 (Doxorubicin-anti-CD99)NanoValent Pharmaceuticals
- NV102 (Doxorubicin-anti-CD19)NanoValent Pharmaceuticals
- NV103 (Irinotecan-anti-CD99)NanoValent Pharmaceuticals
- OBI-999 | Anti-Globo H ADCOBI Pharma
- OMTX503 (Anti-MTX3:Nigrin Immunoconjugate)Oncomatryx Biopharma
- OMTX705 (Anti-MTX5:Cytolysin ADC)Oncomatryx Biopharma
- OXS-1550 (DT2219ARL)GT Biopharma. Previously known as Oxis Biotech (Georgetown Translational Pharmaceuticals)
- PCA062 (PCA-062)ImmunogGen and Novartis
- PEN-221Tarveda Therapeutics
- PF 06263507 (A1-mcMMAF | Anti-5T4 monoclonal antibody | PF-06263507 | PF06263507)Oxford BioMedica; Pfizer (Wyeth)
- PF-06647263 (anti-EFNA4-ADC)Pfizer
- PF-06650808 (Anti-NOTCH3 ADC)Pfizer (Wyeth)
- PF-06664178 | PF06664178 | PF 06664178Pfizer (Wyeth)
- PF-06688992 | PF06688992Memorial Sloan-Kettering Cancer Center; Pfizer
- PF-06804103 (Anti-NG-HER2 ADC)Pfizer
- Pinatuzumab vedotin (RG-7593 / DCDT2980S / DCDT-2989S)Genentech / Roche, F. Hoffmann-La Roche (Roche)
- Polatuzumab vedotin (RG-7596 / DCDS4501A / DCDS-4501A)Genentech / Roche, F. Hoffmann-La Roche
- PSMA-ADCProgenics Pharmaceuticals, Inc. (Tarrytown NY USA)
- Q5-Drug ConjugateAlteogen
- RC-48 (RC 48-ADC)Yantai Rongchang Biological Engineering (RemeGen)
- REGN2878-DM1 (Anti-PRLR-ADC)Regeneron
- RG-7598 (DFRF 4539A / RG7598 / RG 7598)Genentech/Roche
- RG-7841 (Anti-Ly6E / DLYE5953A)Genentech/Roche (in collaboration with Seattle Genetic)
- RG7986Genentech/Roche
- RM-1929Aspyrian Therapeutics, Inc.
- Rovalpituzumab tesirine (Rova-T | SC0001)Stemcentrx (now part of AbbVie)
- Sacituzumab govitecan (IMMU-132 / hRS7-SN38)Immunomedics
- Samrotamab vedotinAbbVie
- SAR 566658 (SAR566658)Sanofi; ImmunoGen
- SAR408701 | SAR 408701Sanofi | ImmunoGen
- SAR428926ImmunoGen; Sanofi
- Satoreotide tetraxetan
- SC-006AbbVie | Stemcentrx
- SC16LD6.5Stem CentRx
- SGN CD70 A | SGN-CD70A (superseding SGN-75)Seattle Genetics
- SGN-15 (BMS-182248, BR96-DOX)Seattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)
- SGN-CD123A
- SGN-CD19BSeattle Genetics
- SGN-CD352aSeattle Genetics
- Sirtratumab vedotin (ASG-15ME)Co-developed by Agensys/Astellas and Seattle Genetics
- SNG-8023 ADCShenogen Pharma Group
- Sofituzumab vedotin (Anti-MUC16 ADC / RG7458 / DMUC5754A)Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
- ST1Siamab Therapeutics
- STRO-001 (Anti-CD74-ADC)Sutro Biopharma
- SΤRO-002Sutro Biopharma
- Tacatuzumab Tetraxetan
- Telisotuzumab Vedotin (ABBV 399; ABBV399)AbbVie
- TGM-001Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-002Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-003Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-004Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- TGM-005Targetome SA, a spin-off from the University of Liège (ULg), Belgium.
- Tisotumab Vedotin (HuMax®-TF-ADC)Co-developed by Genmab and Seattle Genetics
- Trastuzumab deruxtecan (DS-8201, DS-8201a)Daiichi Sankyo Inc.
- Trastuzumab duocarmazine (SYD985)Synthon Biopharmaceuticals
- Trastuzumab-emtansine (T-DM1)Genentech/Roche
- TRPH-222 (CD22-4AP)Triphase Accelerator Corporation, in collaboration with Celgene
- U3-1402 (HER3 ADC)Daiichi Sankyo
- Vadastuximab talirine (SGN-CD33A)Seattle Genetics
- Vandortuzumab vedotin (RG7450; DSTP3086S)Genentech/ F. Hoffmann-La Roche (Roche)
- VIS705Visterra
- Vorsetuzumab mafodotin (SGN-75)Seattle genetics
- VYNFINIT® | Vintafolide (EC145/MK 8109)Endocyte, Merck/MSD
- XMT-1522Mersana Therapeutics in collaboration with Takeda
- XMT-1536Mersana Therapeutics
- ZV05-ADC (5T4-MMAF ADC)Zova Biotherapeutics (Zova Bio); Concortis Biotherapeutics (a subsidiary of Sorrento Therapeutics)
- ZV203Concortis Biotherapeutics
Recommended Blogs Posts
Eric Rosenthal Reports | A Personal Remembrance of Two Giants of Oncology: Jim and Jimmie Holland
03 April, 2018
James F. Holland, MD, one of the pioneers of combination chemotherapy and cancer cooperative group research, died at the age of 92 on March 22. His wife, Jimmie C. Holland, MD, who was considered the founder...
PepTalk: The Protein Science Week – New Horizons, New Goals
02 January, 2018
This year PepTalk: The Protein Science Week, one of the largest annual gatherings of protein science researchers in the world - now in its 17th year - attracts nearly 1,300 experts from academia, biotech and ...